Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Acta Crystallogr D Struct Biol ; 80(Pt 2): 123-136, 2024 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-38289714

RESUMEN

To identify starting points for therapeutics targeting SARS-CoV-2, the Paul Scherrer Institute and Idorsia decided to collaboratively perform an X-ray crystallographic fragment screen against its main protease. Fragment-based screening was carried out using crystals with a pronounced open conformation of the substrate-binding pocket. Of 631 soaked fragments, a total of 29 hits bound either in the active site (24 hits), a remote binding pocket (three hits) or at crystal-packing interfaces (two hits). Notably, two fragments with a pose that was sterically incompatible with a more occluded crystal form were identified. Two isatin-based electrophilic fragments bound covalently to the catalytic cysteine residue. The structures also revealed a surprisingly strong influence of the crystal form on the binding pose of three published fragments used as positive controls, with implications for fragment screening by crystallography.


Asunto(s)
COVID-19 , SARS-CoV-2 , Humanos , Dominio Catalítico , Proteasas 3C de Coronavirus , Cristalografía por Rayos X
2.
Bioorg Med Chem Lett ; 22(21): 6705-11, 2012 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-23006603

RESUMEN

A series of 2-amino-[1,8]-naphthyridine-3-carboxamides (ANCs) with potent inhibition of bacterial NAD(+)-dependent DNA ligases (LigAs) evolved from a 2,4-diaminopteridine derivative discovered by HTS. The design was guided by several highly resolved X-ray structures of our inhibitors in complex with either Streptococcus pneumoniae or Escherichia coli LigA. The structure-activity-relationship based on the ANC scaffold is discussed. The in-depth characterization of 2-amino-6-bromo-7-(trifluoromethyl)-[1,8]-naphthyridine-3-carboxamide, which displayed promising in vitro (MIC Staphylococcus aureus 1 mg/L) and in vivo anti-staphylococcal activity, is presented.


Asunto(s)
Antibacterianos/síntesis química , Antibacterianos/farmacología , ADN Ligasas/antagonistas & inhibidores , Diseño de Fármacos , Staphylococcus/efectos de los fármacos , Animales , Antibacterianos/química , Antibacterianos/uso terapéutico , Cristalografía por Rayos X , ADN Bacteriano/antagonistas & inhibidores , Concentración 50 Inhibidora , Ratones , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Ratas , Infecciones Estafilocócicas/tratamiento farmacológico , Relación Estructura-Actividad
3.
PLoS One ; 13(6): e0199639, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29949628

RESUMEN

The use of the tellurium-centered Anderson-Evans polyoxotungstate [TeW6O24]6- (TEW) as a crystallization additive has been described. Here, we present the use of TEW as an additive in the crystallization screening of the nucleotide binding domain (NBD) of HSP70. Crystallization screening of the HSP70 NBD in the absence of TEW using a standard commercial screen resulted in a single crystal form. An identical crystallization screen of the HSP70 NBD in the presence of TEW resulted in both the "TEW free" crystal form and an additional crystal form with a different crystal packing. TEW binding was observed in both crystal forms, either as a well-defined molecule or in overlapping alternate positions suggesting translational disorder. The structures were solved by both molecular replacement and single wavelength anomalous diffraction (SAD) using the anomalous signal of a single bound molecule of TEW. This study adds one more example of TEW binding to a protein and influencing its crystallization behavior.


Asunto(s)
Proteínas HSP70 de Choque Térmico/química , Sitios de Unión , Cristalización , Escherichia coli , Fluorometría , Estructura Molecular , Estabilidad Proteica , Desplegamiento Proteico , Temperatura
4.
J Med Chem ; 60(9): 3755-3775, 2017 05 11.
Artículo en Inglés | MEDLINE | ID: mdl-28406299

RESUMEN

Our strategy to combat resistant bacteria consisted of targeting the GyrB/ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotics. Screening around the minimal ethyl urea binding motif led to the identification of isoquinoline ethyl urea 13 as a promising starting point for fragment evolution. The optimization was guided by structure-based design and focused on antibacterial activity in vitro and in vivo, culminating in the discovery of unprecedented substituents able to interact with conserved residues within the ATP-binding site. A detailed characterization of the lead compound highlighted the potential for treatment of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae, and the possibility to offer patients an intravenous-to-oral switch therapy was supported by the identification of a suitable prodrug concept. Eventually, hERG K-channel block was identified as the main limitation of this chemical series, and efforts toward its minimization are reported.


Asunto(s)
Antibacterianos/farmacología , Isoquinolinas/farmacología , Animales , Antibacterianos/química , Área Bajo la Curva , Descubrimiento de Drogas , Bacterias Gramnegativas/efectos de los fármacos , Semivida , Enlace de Hidrógeno , Isoquinolinas/química , Isoquinolinas/farmacocinética , Isoquinolinas/uso terapéutico , Pruebas de Sensibilidad Microbiana , Canales de Potasio/efectos de los fármacos , Ratas , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/microbiología , Solubilidad , Urea/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA